No. 1 online shop for research peptides in Europe

Pre-Filled Pen

Research use only

GW-0742 50mg / 1.5mL

€95.00

VAT included. Shipping calculated at checkout.

1

In stock

  • ≥99% purity
  • HPLC & LC-MS analysed
  • Stabilised formula
  • The world's first brand of peptides in a pen

Secure delivery

Secure delivery with FedEx within 1–2 business days after payment confirmation

Payment methods

  • Bank transfer
How the pen worksVideo in English

What is GW0742?

GW0742 is a synthetic peroxisome proliferator-activated receptor delta (PPAR-δ) agonist investigated as a potential regulator of metabolic and energy processes. Structurally related to GW501516, GW0742 exhibits higher selectivity and affinity for PPAR-δ, making it a valuable research target targeting the regulation of lipid and glucose metabolism, energy balance, and muscle oxidation. Due to its specific activity, the compound is used in a laboratory environment to analyze molecular mechanisms related to mitochondrial function, metabolic flexibility and physical endurance.

GW0742 Mechanism of Action:

GW0742 binds selectively to PPAR-δ receptors – nuclear receptors involved in the regulation of the expression of genes related to energy metabolism. Activation of these receptors leads to stimulation of fatty acid oxidation, improvement of mitochondrial activity and increase of energy efficiency in muscle tissue. Furthermore, GW0742 modulates glucose homeostasis and affects the lipid profile without directly affecting the hormonal axis. It is this mechanism that makes it particularly interesting in scientific research focused on metabolic diseases, endurance training and energy adaptation.

Potential scientifically supported benefits of GW0742:

GW0742 has been the subject of a number of analyzes in which the following potential effects have been observed:

  • Increased fat burning by stimulating β-oxidation;
  • Increased mitochondrial activity and energy efficiency in muscles;
  • Improved glucose sensitivity and glycemic control;
  • Potentially supporting physical endurance;
  • Anti-inflammatory modulation through regulation of PPAR-δ dependent pathways;
  • Maintaining a healthy lipid profile.

Due to these observations, GW0742 is frequently included in protocols for the study of metabolic disorders, sports physiology and cardiometabolic mechanisms.

Comparison of GW0742 with other SARMs and metabolic agonists

GW0742 is a synthetic PPAR-δ (peroxisome proliferator-activated receptor delta) agonist that is not a SARM, but is often grouped with them due to its similar use in metabolic regulation, lipid control, and endurance research protocols. It is most commonly compared to Cardarine (GW501516), Stenabolic (SR9009) and sometimes to lighter SARMs such as Ostarine (MK2866) when combined for body recomposition purposes.

Compared to Cardarine, GW0742 has a higher affinity for the PPAR-δ receptor, making it more potent in models investigating fat oxidation and improvement of mitochondrial function. Both molecules promote the use of fat as a primary energy source, but GW0742 is often preferred in more targeted metabolic studies, especially when a more selective effect on energy metabolism in muscle tissue is sought.

Compared to Stenabolic (SR9009), which acts by activating REV-ERBα and affecting circadian rhythms, GW0742 is more focused on the deep regulation of lipid metabolism and glucose homeostasis, without directly affecting the biological clock. While SR9009 improves energy capacity and endurance through mitochondrial activity, GW0742 does so by activating metabolic genes responsible for fatty acid oxidation.

In the context of SARMs such as Ostarine or Ligandrol, which affect muscle mass through androgen receptors, GW0742 stands out as a completely non-hormonal metabolic modulator suitable for studies where the goal is fat burning, improved insulin sensitivity and metabolic flexibility.

Dosage and administration of GW0742 in research protocols:

Recommended study schedule: 5-6 units once daily for 4-6 weeks, followed by a 2-4 week rest period.

1 unit =
333mcg.

Total quantity in pen: 150 units

Possible side effects of GW0742:

While GW0742 shows promising results, it is important to consider its safety profile. Its observed negative effects include:

  • Changes in lipid metabolism during long-term use;
  • Lack of long-term data on chronic exposure;
  • Adverse interactions with other PPAR-modulating compounds.

Adherence to the optimal dosage and control of the duration of application play a key role in limiting the occurrence of side effects.

More from SARMs

Shopping information

Delivery

Delivered within 1–2 business days after your payment has been confirmed.

  • Shipped with FedEx
  • Shipping costs: €8.90
Shipping policy

Payment

  • Bank transfer

Pay securely by bank transfer. Your order is dispatched as soon as your payment has been confirmed.

For research use only

For scientific, laboratory, analytical and research use only, including as a reference standard in HPLC analyses – not for use in humans or animals.

Read more

All products are intended solely and exclusively for scientific, laboratory, analytical and research purposes, including use as reference standards in HPLC analyses. They are not intended for use in humans or animals, including for the diagnosis, treatment or prevention of disease, and are not approved medicinal products.

Contact & service

Questions about an order, delivery or a product? Our customer service team is happy to help.

ContactFAQ